Pancreatic Cancer Research

ResearcherNorthwell HealthActive in the last 2 years

Sepideh Gholami

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9294-1710; OpenAlex author ID A5028462034. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 4 papers · 2025: 4 papers · 2026: 3 papers

Papers 12

  1. Medicaid Expansion Timing and Pancreatic Cancer Resection Rates and Survival. Co-author DOI 10.1001/jamasurg.2026.0057↗
  2. Survival Disparities in Early-Onset Pancreatic Cancer (EOPC): The Role of Socioeconomic Status and Healthcare Access. Co-author DOI 10.1002/jso.70148↗
  3. Implantable Microdevices for In Vivo Assessment of Chemotherapy Response in Patient Derived Organoid Orthotopic Pancreatic Cancer Models. Co-author DOI 10.1097/sla.0000000000007071↗
  4. Evaluating the Association of Area Deprivation Index (ADI) on Postoperative Outcomes in Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27996↗
  5. Impact of Environmental Quality on Pancreatic Cancer Outcomes Post Pancreatoduodenectomy: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-025-01254-4↗
  6. Standard-Adherent Surgery and Guideline-Based Therapy in Pancreatic Cancer: A Multicenter Analysis. Co-author DOI 10.1245/s10434-025-17467-7↗
  7. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32020103↗
  8. Outcomes of minimally invasive vs. open pancreatoduodenectomies in pancreatic adenocarcinoma: analysis of ACS-NSQIP data. Co-author DOI 10.1007/s00423-024-03454-1↗
  9. Modified 5-Item Frailty Index (mFI-5) may predict postoperative outcomes after pancreatoduodenectomy for pancreatic Cancer. Co-author DOI 10.1007/s00423-024-03483-w↗
  10. Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S. Co-author DOI 10.1007/s12029-024-01119-2↗
  11. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational s… Co-author DOI 10.1016/j.esmogo.2024.100042↗
  12. Evaluation of Adherence to Venous Thromboembolism Prophylaxis Guidelines Among US Adults After Pancreatic Cancer Surgery. Last author DOI 10.1001/jamasurg.2022.2590↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Danielle K. DePeralta · 9 shared papers, 2024–2026 · strength 2.24
  2. Daniel A. King · 8 shared papers, 2024–2026 · strength 1.90
  3. Marcovalerio Melis · 7 shared papers, 2024–2026 · strength 1.70
  4. Elliot Newman · 7 shared papers, 2024–2026 · strength 1.70
  5. Abdullah Khalid · 7 shared papers, 2024–2026 · strength 1.70
  6. Oliver J. Standring · 6 shared papers, 2024–2026 · strength 1.47
  7. Matthew John Weiss · 6 shared papers, 2024–2025 · strength 1.39
  8. Lyudmyla Demyan · 4 shared papers, 2024–2026 · strength 0.93
  9. Shamsher Ali Pasha · 4 shared papers, 2024–2025 · strength 0.90
  10. Matthew J. Weiss · 2 shared papers, 2026 · strength 0.56
  11. Julien T. Hohenleitner · 2 shared papers, 2026 · strength 0.54
  12. M. Weiss · 1 shared paper, 2026 · strength 0.30
  13. Gerardo A. Vitiello · 1 shared paper, 2026 · strength 0.30
  14. Shruti Koti · 1 shared paper, 2026 · strength 0.24
  15. Youngkyu Park · 1 shared paper, 2026 · strength 0.24
  16. David Arthur Tuveson · 1 shared paper, 2026 · strength 0.24
  17. Craig Devoe · 1 shared paper, 2025 · strength 0.24
  18. Grace Wu · 1 shared paper, 2025 · strength 0.24
  19. Travis Edward Grotz · 1 shared paper, 2025 · strength 0.24
  20. Cornelius A. Thiels · 1 shared paper, 2025 · strength 0.24
  21. Matthew John Weiss · 1 shared paper, 2025 · strength 0.24
  22. Mustafa Raoof · 1 shared paper, 2025 · strength 0.24
  23. Julie I. Hallet · 1 shared paper, 2022 · strength 0.17
  24. Lauren M. Perry · 1 shared paper, 2022 · strength 0.17
  25. Robert J. Canter · 1 shared paper, 2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.